Pneumococcal vaccines: Understanding centers for disease control and prevention recommendations

Annals of the American Thoracic Society

Volumn 11, Issue 6, 2014, Pages 969-974

  Mirsaeidi, Mehdi ^a   Schraufnagel, Dean E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Adults; PCV13; Pneumococcal vaccine; PPV23; Vaccination

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CHILL; CHRONIC DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HEALTH CENTER; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INFLUENZA VACCINATION; INJECTION SITE PAIN; NONHUMAN; PRURITUS; REVACCINATION; SKIN REDNESS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84908217031     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201401-042CME     Document Type: Article

References (47)

1. World Health Organization. Pneumococcal vaccines. Geneva, Switzerland: World Health Organization; 2013. Available from: http://www.who.int/biologicals/areas/vaccines/pneumo/en/
2. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, Cibulskis R, et al.; Child Health Epidemiology Reference Group of WHO and UNICEF. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 2010;375:1969-1987.
3. Yu H, Rubin J, Dunning S, Li S, Sato R. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc 2012;60:2137-2143.
4. Aliberti S, Kaye KS. The changing microbiologic epidemiology of community-acquired pneumonia. Postgrad Med 2013;125:31-42.
5. Robinson KA, Baughman W, Rothrock G, Barrett NL, Pass M, Lexau C, Damaske B, Stefonek K, Barnes B, Patterson J, et al.; Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program Network. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001;285:1729-1735.
6. U.S. Department of Health and Human Services. Healthy people 2010 [CDC website]. Available from: http://wonder.cdc.gov/data2010/
7. High KP. Overcoming barriers to adult immunization. J Am Osteopath Assoc 2009;109(6, Suppl 2):S25-S28.
8. Appel A. Improving adult immunization rates: overcoming barriers. Am Fam Physician 2011;84:977-978.
9. Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI. Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011;10:1143-1167.
10. Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II. Clin Infect Dis 2000;30:122-140.
11. Musher DM, Alexandraki I, Graviss EA, Yanbeiy N, Eid A, Inderias LA, Phan HM, Solomon E. Bacteremic and nonbacteremic pneumococcal pneumonia: a prospective study. Medicine (Baltimore) 2000;79:210-221.
12. Plevneshi A, Svoboda T, Armstrong I, Tyrrell GJ, Miranda A, Green K, Low D, McGeer A; Toronto Invasive Bacterial Diseases Network. Population-based surveillance for invasive pneumococcal disease in homeless adults in Toronto. PLoS One 2009;4:e7255.
13. Croney CM, Coats MT, Nahm MH, Briles DE, Crain MJ. PspA family distribution, unlike capsular serotype, remains unaltered following introduction of the heptavalent pneumococcal conjugate vaccine. Clin Vaccine Immunol 2012;19:891-896.
14. Licciardi PV, Toh ZQ, Dunne E, Wong SS, Mulholland EK, Tang M, Robins-Browne RM, Satzke C. Protecting against pneumococcal disease: critical interactions between probiotics and the airway microbiome. PLoS Pathog 2012;8:e1002652.
15. Cohen JM, Khandavilli S, Camberlein E, Hyams C, Baxendale HE, Brown JS. Protective contributions against invasive Streptococcus pneumoniae pneumonia of antibody and Th17-cell responses to nasopharyngeal colonisation. PLoS One 2011;6:e25558.
16. Gradstedt H, Iovino F, Bijlsma JJ. Streptococcus pneumoniae invades endothelial host cells via multiple pathways and is killed in a lysosome dependent manner. PLoS One 2013;8:e65626.
17. Bergmann S, Hammerschmidt S. Versatility of pneumococcal surface proteins. Microbiology 2006;152:295-303.
18. Pracht D, Elm C, Gerber J, Bergmann S, Rohde M, Seiler M, Kim KS, Jenkinson HF, Nau R, Hammerschmidt S. PavA of Streptococcus pneumoniae modulates adherence, invasion, and meningeal inflammation. Infect Immun 2005;73:2680-2689.
19. Orihuela CJ, Mahdavi J, Thornton J, Mann B, Wooldridge KG, Abouseada N, Oldfield NJ, Self T, Ala 'Aldeen DA, Tuomanen EI. Laminin receptor initiates bacterial contact with the blood brain barrier in experimental meningitis models. J Clin Invest 2009;119:1638-1646.
20. Royle SJ. The cellular functions of clathrin. Cell Mol Life Sci 2006;63: 1823-1832.
21. Austrian R. A brief history of pneumococcal vaccines. Drugs Aging 1999;15:1-10.
22. Smillie WG, Warnock GH, White HJ. A study of a type I Pneumococcus epidemic at the State Hospital of Worcester, Mass. Am J Public Health Nations Health 1938;28:293-302.
23. Macleod CMH, Hodges RG, Heidelberger M, Bernhard WG. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J Exp Med 1945;82:445-465.
24. Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010;59:258-261.
25. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, et al.; Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737-1746.
26. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1997;176:1100-1104.
27. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995;21:616-620.
28. McDonald E, Jarrett MP, Schiffman G, Grayzel AI. Persistence of pneumococcal antibodies after immunization in patients with systemic lupus erythematosus. J Rheumatol 1984;11:306-308.
29. Kumar D, Welsh B, Siegal D, Chen MH, Humar A. Immunogenicity of pneumococcal vaccine in renal transplant recipients-three year follow-up of a randomized trial. Am J Transplant 2007;7:633-638.
30. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 1999;18:524-530.
31. Chen M, Hisatomi Y, Furumoto A, Kawakami K, Masaki H, Nagatake T, Sueyasu Y, Iwanaga T, Aizawa H, Oishi K. Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination. Clin Vaccine Immunol 2007;14:139-145.
32. Musher DM, Manof SB, Liss C, McFetridge RD, Marchese RD, Bushnell B, Alvarez F, Painter C, Blum MD, Silber JL. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middle-aged and older adults. J Infect Dis 2010;201:516-524.
33. Jackson LA, Benson P, Sneller VP, Butler JC, Thompson RS, Chen RT, Lewis LS, Carlone G, DeStefano F, Holder P, et al. Safety of revaccination with pneumococcal polysaccharide vaccine. JAMA 1999;281:243-248.
34. Grabenstein JD, Manoff SB. Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adults. Vaccine 2012;30:4435-4444.
35. Jackson LA, Janoff EN. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin Infect Dis 2008;47:1328-1338.
36. Johnstone J, Eurich DT, Minhas JK, Marrie TJ, Majumdar SR. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis 2010;51:15-22.
37. Kumar D, Chen MH, Welsh B, Siegal D, Cobos I, Messner HA, Lipton J, Humar A. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin Infect Dis 2007;45:1576-1582.
38. Hung CC, Chang SY, Su CT, Chen YY, Chang SF, Yang CY, Liu WC, Wu CH, Chang SC. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy. HIV Med 2010;11:54-63.
39. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2013;62:521-524.
40. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012;61:816-819.
41. Luján M, Burgos J, Gallego M, Falcó V, Bermudo G, Planes A, Fontanals D, Peghin M, Monsó E, Rello J. Effects of immunocompromise and comorbidities on pneumococcal serotypes causing invasive respiratory infection in adults: implications for vaccine strategies. Clin Infect Dis 2013;57:1722-1730.
42. Smith KJ, Nowalk MP, Raymund M, Zimmerman RK. Costeffectiveness of pneumococcal conjugate vaccination in immunocompromised adults. Vaccine 2013;31:3950-3956.
43. Wong A, Marrie TJ, Garg S, Kellner JD, Tyrrell GJ, Group S; SPAT (Streptococcus pneumoniae Alberta Team) Group. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol Infect 2010;138:1804-1810.
44. Debbache K, Varon E, Hicheri Y, Legrand P, Donay JL, Ribaud P, Cordonnier C. The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France: are the serotypes covered by the available anti-pneumococcal vaccines? Clin Microbiol Infect 2009;15:865-868.
45. Hammitt LL, Bulkow LR, Singleton RJ, Nuorti JP, Hummel KB, Miernyk KM, Zanis C, Whaley M, Romero-Steiner S, Butler JC, et al. Repeat revaccination with 23-valent pneumococcal polysaccharide vaccine among adults aged 55-74 years living in Alaska: no evidence of hyporesponsiveness. Vaccine 2011;29:2287-2295.
46. Mahamat A, Daurès JP, de Wzieres B. Additive preventive effect of influenza and pneumococcal vaccines in the elderly: results of a large cohort study. Hum Vaccin Immunother 2013;9:128-135.
47. Chan TC, Hung IF, Luk JK, Shea YF, Chan FH, Woo PC, Chu LW. Prevention of mortality and pneumonia among nursing home older adults by dual pneumococcal and seasonal influenza vaccination during a pandemic caused by novel pandemic influenza A (H1N1). J Am Med Dir Assoc 2012;13:698-703.